perfectly normal." The reactions described by Leventhal and Bothe et al. would later be coined into the term "osseointegration" by Per-Ingvar Brånemark of Sweden. In 1952, Brånemark did an experiment where he used a titanium implant chamber to study blood flow in rabbit bone. At the end of the experiment, when it became time to remove the titanium chambers from the bone, he discovered that the bone had integrated so completely with the implant that the chamber could not be removed. Brånemark called this "osseointegration", and, like Bothe et al. and Leventhal before him, saw the possibilities for human use. In dentistry the implementation of osseointegration started in the mid-1960s as a result of Brånemark's work. In 1965 Brånemark, who was at the time Professor of Anatomy at University of Gothenburg, placed dental implants into the first human patient – Gösta Larsson. This patient had a cleft palate defect and needed implants to support a palatal obturator. Gösta Larsson died in 2005, with the original implants still in place after 40 years of function. In the mid-1970s Brånemark entered into a commercial partnership with the Swedish defense company Bofors to manufacture dental implants and the instrumentation required for their placement. Eventually an offshoot of Bofors, Nobel Pharma, was created to concentrate on this product line. Nobel Pharma subsequently became Nobel Biocare. Brånemark spent almost 30 years fighting the scientific community for acceptance of osseointegration as a viable treatment. In Sweden he was often openly ridiculed at science conferences. His university stopped funding for his research, forcing him to open a private clinic to continue treating patients. Eventually an emerging breed of young academics started to notice the work being done in Sweden. Toronto's George Zarb, a Maltese-born Canadian prosthodontist, was instrumental in bringing the concept of osseointegration to the wider world. The 1983 Toronto Conference is generally considered to be the turning point, when finally the worldwide scientific community accepted Brånemark's work. Osseointegration is now a highly predictable and common treatment modality. Since 2010, Al Muderis in Sydney, Australia, used a high tensile strength titanium implant with plasma sprayed surface as an intramedullary prosthesis that is inserted into the bone residuum of amputees and then connect through an opening in the skin to a robotic limb prosthesis. This lets amputees mobilize with more comfort and less energy consumption. Al Muderis also published the first series of combining osseointegration prosthesis with